Sinovac Biotech Ltd. – NASDAQ:SVA

Sinovac Biotech Ltd. stock price today

$6.47
Financial Health
0
1
2
3
4
5
6
7
8
9

Sinovac Biotech Ltd. key metrics

Market Cap
464.93M
Enterprise value
N/A
P/E
6.66
EV/Sales
-12.01
EV/EBITDA
-41.65
Price/Sales
1.25
Price/Book
0.06
PEG ratio
N/A
EPS
38.78
Revenue
24.46B
EBITDA
7.36B
Income
3.70B
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
21.61%
Oper. margin
42.23%
Gross margin
86.84%
EBIT margin
42.23%
EBITDA margin
30.1%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Sinovac Biotech Ltd. stock price history

Sinovac Biotech Ltd. stock forecast

Sinovac Biotech Ltd. financial statements

Sinovac Biotech Ltd. (NASDAQ:SVA): Profit margin
Dec 2021 8.39B 3.35B 40.02%
Dec 2021 14.71B -160.48M -1.09%
Jun 2022 1.21B 484.51M 39.97%
Jun 2023 140.40M 16.91M 12.05%
Sinovac Biotech Ltd. (NASDAQ:SVA): Analyst Estimates
2025 742.63M -11.95M -1.61%
  • Analysts Price target

  • Financials & Ratios estimates

Sinovac Biotech Ltd. (NASDAQ:SVA): Earnings per share (EPS)
2023-01-30 -0.045 -0.03
0%
Yield TTM
Sinovac Biotech Ltd. (NASDAQ:SVA): Payout ratio
Payout ratio 0%
Sinovac Biotech Ltd. (NASDAQ:SVA): Dividend Yield
2019
2020
2021 291.95%
2022 40.88%
2023 50.91%
Sinovac Biotech Ltd. (NASDAQ:SVA): Debt to assets
Dec 2021 533671750505 503.12B 94.28%
Jun 2022 15065784000 971.92M 6.45%
Dec 2022 14114568000 1.40B 9.93%
Jun 2023 13725010000 1.48B 10.84%
Sinovac Biotech Ltd. (NASDAQ:SVA): Cash Flow
Jun 2021 9.08B -3.27B -29.99M
Dec 2021 6.26B 251.30M -1.86B
Jun 2022 -808.16M -3.58B 11.70M
Jun 2023 -39.99M -2.73B 217.16M

Sinovac Biotech Ltd. alternative data

Sinovac Biotech Ltd. (NASDAQ:SVA): Employee count
Aug 2023 1,959
Sep 2023 1,959
Oct 2023 1,959
Nov 2023 1,959
Dec 2023 1,959
Jan 2024 1,959
Feb 2024 1,959
Mar 2024 1,959
Apr 2024 1,959
May 2024 1,959
Jun 2024 1,959
Jul 2024 1,959

Sinovac Biotech Ltd. other data

5.44% -2.39%
of SVA is owned by hedge funds
6.21M -2.71M
shares is hold by hedge funds

Sinovac Biotech Ltd. (NASDAQ:SVA): Insider trades (number of shares)
Period Buy Sel
Sep 2003 0 12572700
Nov 2003 0 6027870
Transaction Date Insider Security Shares Price per share Total value Source
Sale
IFG INVESTMENTS SERVICES INC 10 percent owner
Common Shares 6,027,870 N/A N/A
Sale
BOWERING TERRY G director, 10 percent owner, off..
Common Shares 6,544,830 N/A N/A
Sale
IFG INVESTMENTS SERVICES INC 10 percent owner
Common Shares 6,027,870 N/A N/A
Insider Compensation
Dr. Weidong Yin Chairman, Chief Executive Officer, Pres, MD, GM & Sec.
Ms. Xiaomei Yin Vice President of Sales & Marketing
Ms. Nan Wang Chief Financial Officer & Vice President of Bus. Devel.
  • What's the price of Sinovac Biotech Ltd. stock today?

    One share of Sinovac Biotech Ltd. stock can currently be purchased for approximately $6.47.

  • When is Sinovac Biotech Ltd.'s next earnings date?

    Unfortunately, Sinovac Biotech Ltd.'s (SVA) next earnings date is currently unknown.

  • Does Sinovac Biotech Ltd. pay dividends?

    No, Sinovac Biotech Ltd. does not pay dividends.

  • How much money does Sinovac Biotech Ltd. make?

    Sinovac Biotech Ltd. has a market capitalization of 464.93M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 69.97% to 448.27M US dollars. Sinovac Biotech Ltd. made a loss 99.92M US dollars in net income (profit) last year or -$0.03 on an earnings per share basis.

  • What is Sinovac Biotech Ltd.'s stock symbol?

    Sinovac Biotech Ltd. is traded on the NASDAQ under the ticker symbol "SVA".

  • What is Sinovac Biotech Ltd.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Sinovac Biotech Ltd.?

    Shares of Sinovac Biotech Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Sinovac Biotech Ltd.'s key executives?

    Sinovac Biotech Ltd.'s management team includes the following people:

    • Dr. Weidong Yin Chairman, Chief Executive Officer, Pres, MD, GM & Sec.
    • Ms. Xiaomei Yin Vice President of Sales & Marketing
    • Ms. Nan Wang Chief Financial Officer & Vice President of Bus. Devel.
  • How many employees does Sinovac Biotech Ltd. have?

    As Jul 2024, Sinovac Biotech Ltd. employs 1,959 workers.

  • When Sinovac Biotech Ltd. went public?

    Sinovac Biotech Ltd. is publicly traded company for more then 21 years since IPO on 26 Sep 2003.

  • What is Sinovac Biotech Ltd.'s official website?

    The official website for Sinovac Biotech Ltd. is sinovacbio.com.

  • How can i contact Sinovac Biotech Ltd.?

    Sinovac Biotech Ltd. can be reached via phone at +86 10 8289 0088.

Sinovac Biotech Ltd. company profile:

Sinovac Biotech Ltd.

sinovacbio.com
Exchange:

NASDAQ

Full time employees:

1,959

Industry:

Biotechnology

Sector:

Healthcare

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

No.39, SHANGDI West Road
Beijing,

CIK: 0001084201
ISIN: AGP8696W1045
: